NCT04346381 2023-09-18
Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
Clinical Trials
10 trialsNCT03871855 2023-06-05
A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Terminated
NCT05699811 2023-04-28
IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors
Chinese PLA General Hospital
Phase 1/2 Recruiting
NCT05809336 2023-04-12
Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors
Beijing Friendship Hospital
Phase 2/3 Completed
NCT02721589 2023-02-28
A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Solid Tumor Subjects
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT05214976 2022-12-22
A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Unknown
NCT03182673 2022-09-01
The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Terminated
NCT04282278 2021-12-10
Study of Anti-PD-1 Antibody Multimodal Combination as First-line Treatment on Time Window of Advanced Solid Tumor
Hebei Medical University Fourth Hospital
Phase 2 Unknown
NCT04832204 2021-04-05
Apatinib Combined With SHR-1210 as Second-line Treatment in Solid Tumors With Only Liver Metastases
Beijing Hospital
Phase 2 Unknown
NCT03171220 2017-06-06
NRT-01
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 1/2 Unknown